Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma
Filip Janku, MD, PhD, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma.
Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma. Researchers concluded that this combination of agents was well tolerated and demonstrated encouraging activity.
<<<
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
